While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis introduces the first approved malaria treatment for newborns and young infants Safer dosing helps lower the risk of ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

Novartis, Pidilite, Aditya Birla Sun Life AMC, Heritage Foods , and D. B. Corp are the 5 key companies to trade ex-dividend ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...